All three are in the same family of compounds: they all activate the GLP-1 receptor, which is the mechanism behind appetite reduction and blood sugar regulation. But that's where the similarity ends. Each one adds something the previous doesn't have, and those additions appear to matter for outcomes.
Semaglutide
Semaglutide (sold as Ozempic for type 2 diabetes and Wegovy for weight loss) targets a single receptor: the GLP-1 receptor. GLP-1 is a hormone your gut releases after eating. It tells your pancreas to release insulin, slows digestion, and signals your brain to reduce appetite. Semaglutide mimics that signal.
It's the most studied compound in this class by a significant margin. Years of large clinical trial data exist for both its metabolic effects and its cardiovascular outcomes. It's also the most widely available and, for many people, covered by insurance in ways the newer compounds aren't yet.
In trials, semaglutide produced average weight loss of around 15% of body weight in people with obesity, a result that was considered striking when it was first published.
Tirzepatide
Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) hits two receptors: GLP-1 and GIP. GIP (Glucose-Dependent Insulinotropic Polypeptide) is a different gut hormone that also plays a role in insulin release and fat metabolism. Activating both receptors at once appears to produce effects that are additive, not just redundant.
In head-to-head trials comparing tirzepatide directly to semaglutide, tirzepatide consistently produced greater average weight loss: around 20–22% of body weight at higher doses, compared to 15% for semaglutide. That's a meaningful difference, not a marginal one.
The leading explanation is that the dual mechanism targets fat metabolism through more than one pathway simultaneously. Whether that translates to better long-term outcomes beyond weight loss (cardiovascular events, metabolic disease progression) is still being studied.
Retatrutide
Retatrutide adds a third receptor to the mix: glucagon. Glucagon is typically thought of as the hormone that raises blood sugar (the opposite of insulin), but it also plays a significant role in fat breakdown and metabolic rate. Activating the glucagon receptor alongside GLP-1 and GIP appears to accelerate fat loss in ways the dual agonists don't fully capture.
Early-phase trial data for retatrutide is striking: some participants showed weight loss exceeding 24% of body weight. That's the highest average seen in this class so far. As of mid-2026, retatrutide is still in clinical trials and does not have FDA approval.
The triple mechanism also raises questions that haven't been fully answered yet. Adding glucagon receptor activation at higher doses has been associated with muscle loss in some trial data, which researchers are actively working through. The side effect profile at therapeutic doses is still being characterized. Promising early results don't mean settled science.
How they compare
| Compound | Receptors Targeted | Avg. Weight Loss (trials) | Approval Status |
|---|---|---|---|
| Semaglutide | GLP-1 | ~15% | FDA approved |
| Tirzepatide | GLP-1 + GIP | ~20–22% | FDA approved |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24%+ | In trials (as of mid-2026) |
What actually matters when comparing them
The mechanism differences are real, and the trial data shows a clear pattern: more receptor targets correlates with greater average weight loss so far. But averages obscure a lot. Individual responses to all three compounds vary significantly. Some people respond strongly to semaglutide; others do not. Some tolerate tirzepatide well; others do not. Those individual differences aren't yet predictable from any biomarker or profile.
For most people considering these compounds in a clinical context, the conversation with a prescriber centers on factors that have nothing to do with mechanism: what your health history looks like, what side effects you can tolerate, what your insurance covers, and whether a compound that isn't yet approved is even a realistic option. Retatrutide, for example, is currently only available as a research compound, not a prescription option for most people.
The mechanism comparison is worth understanding. But "more receptors = better for me" isn't a conclusion the research supports yet.